Last updated on November 2017

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease


Brief description of study

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

Detailed Study Description

The primary objective of the study is to evaluate the efficacy of monthly doses of Aducanumab in slowing cognitive and functional impairment.

Clinical Study Identifier: TX7246

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Jennifer Cavin

NeuroStudies.net, LLC
Decatur, GA USA
  Connect »

Jill Smith

University of South Florida- Byrd Alzheimer's Institute
Tampa, FL USA
  Connect »

Jennifer Cavin

NeuroStudies.net, LLC
Decatur, GA USA
  Connect »